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Background: The increasing prevalence of cardiometabolic disease (CMD) in combination with an ageing
population is a major public health problem. Early detection and management of individuals at risk for CMD is
required to prevent future health problems with associated costs. General practice is the optimal health care setting
to accomplish this goal. Prevention programs for identification and treatment of patients with an increased risk for
CMD in primary care have been proven feasible. However, the effectiveness and cost-effectiveness have yet to be
demonstrated. The ‘Personalized Prevention Approach for CardioMetabolic Risk’ (PPA CMR) is such a prevention
program. The objective of the INTEGRATE study is to investigate the effectiveness and cost-effectiveness of PPA
CMR, as well as to establish determinants for participation and compliance.
Methods: The INTEGRATE study is designed as a stepped-wedge randomized controlled trial with a waiting list
control group. In approximately 40 general practices, all enlisted patients without CMD aged 45–70 years, are
invited to participate in PPA CMR. After an online risk estimation, patients with a score above risk threshold are
invited to the GP for additional measurements, detailed risk profiling and tailored treatment of risk factors through
medication and/or lifestyle counseling. At baseline and after twelve months of follow-up lifestyle, health and work
status of all participants are established with online questionnaires. Additionally after twelve months, we will
determine health care utilization, costs of PPA CMR and compliance. Primary endpoints are the number of newly
detected patients with CMD and changes in individual risk factors between the intervention and waiting list control
group. Medical data will be extracted from the GPs’ electronic medical records. In order to assess factors related to
participation, we will send questionnaires to non-participants and assess characteristics of participating practices.
For all participants, additional demographic characteristics will be available through Statistics Netherlands.
Discussion: The INTEGRATE study will provide insight into the effectiveness and cost-effectiveness of PPA CMR as
well as determinants for participation and compliance, which represents essential information to guide further
large-scale implementation of primary prevention programs for CMD.
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Figure 1 Flowchart of the study design.
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The increasing prevalence of cardiometabolic disease
(CMD), including cardiovascular disease, diabetes melli-
tus and chronic kidney disease, in combination with an
ageing population is a major public health problem.
CMD mainly results from a long lasting exposure to an
unhealthy lifestyle. The most important lifestyle related
causes of morbidity and mortality are smoking, obesity
and physical inactivity [1]. The increasing number of
people with an unhealthy lifestyle is expected to lead to
a rising prevalence of CMD in the coming decades [2-4].
Therefore, early detection and adequate management of
individuals at risk for CMD is urgent in order to prevent
future health problems and further increase in health
care costs.
Screening for CMD could be more efficient when
structurally embedded in primary health care [5,6]. Gen-
eral practitioners (GPs) can play an important role in
preventing CMD [7]. General practice is the optimal set-
ting for identifying and treating patients at risk [8]. GPs
provide integrated health care, are aware of the psycho-
social context and have a longstanding relationship with
their patients.
Several prevention programs for CMD in primary care
have been developed. These programs aim to identify
patients at risk for CMD and to offer lifestyle advice and
treatment when indicated [9-13]. The core elements of
these programs are evidence-based and the feasibility
has been positively evaluated [9-12,14-18]. Different
parties have initiated implementation by offering their
program to subgroups within the general population.
However, the effectiveness and cost-effectiveness of pre-
vention programs for CMD need to be established first
to justify broad implementation in primary care [19].
An effective prevention program also requires struc-
tured health care, willingness to participate and compli-
ance of patients at risk. So far, little is known about
the characteristics of practices, participants and non-
participants in prevention programs in primary care
[20-22]. Knowledge about determinants for non-
participation will support the development of tailored
strategies to reach specific subgroups. In the INTE-
GRATE study we aim to assess the effectiveness of a
CMD prevention program coupled to an individualized
lifestyle intervention. This entire program will be fur-
ther referred to as “Personalized Prevention Approach
for CardioMetabolic Risk” (PPA CMR). Therefore, the
objective of the INTEGRATE study is to investigate the
effectiveness and cost-effectiveness of PPA CMR, as well
as to asses determinants for successful participation in
PPA CMR. In this paper we will describe the design of
the study and we will discuss the choices that have been
made for the intervention and with regard to outcome
measures.Methods
Study design
The INTEGRATE study is a clustered stepped-wedge
randomized controlled trial with a waiting list control
group. A flowchart of the study and a timeline is shown
in Figures 1 and 2, respectively. All participants are of-
fered the intervention (PPA CMR) during the study
period. The intervention is implemented over four time
periods, in randomly ordered subgroups. The interven-
tion group starts with PPA CMR at onset of the study,
the control group starts with PPA CMR one year later.
The one year waiting list period is necessary to measure
natural changes in lifestyle and to estimate the number
of patients with newly detected CMD without exposure
to PPA CMR.
Figure 2 Timeline per practice and overview of measures. Legend: • = All patients, o = Patients with an increased risk for CMD.
Q = questionnaire, P = primary outcome measure, S = secondary outcome measure.
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The study will be conducted in approximately 40 general
practices in the Netherlands, a representative sample of
all Dutch general practices with regard to the distribution
in rural/urban and solo/group practices. Inclusion and
exclusion criteria for practices and patients are shown in
Table 1.
Inclusion criterion for practices:
 The use of an Electronic Medical Record (EMR)
system, from which electronic data extraction is
possible, covering approximately 90% of all Dutch
general practices.
Exclusion criterion for practices:
 Previously performed systematic CMD screening of
the entire or a non-random sample of the practice
population.
All eligible patients of the included practices (approxi-
mately 28.500 patients) receive an invitation letter from
their GP to participate in the INTEGRATE study.
Inclusion criterion for patients:Table 1 Inclusion and exclusion criteria for practices and part
Inclusion Exclusio
General practices • Use of common Electronic Medical Record










Lipid m Age between 45 and 70 years, which is according to
the guideline of the Dutch College of GPs [13].
Exclusion criteria for patients:
 Previous diagnosis of CMD according to EMR
(see Table 1 for list of International Classification of
Primary Care (ICPC-1)-coded diagnoses [23]).
 Receiving antihypertensive and/or lipid-lowering
treatment.
Randomization
Eligible patients are randomized within each general
practice into four time groups: two intervention groups
and two waiting list control groups. We will use the
statistical software program Stata version 12 for the
randomization. Every four months a new group starts
with the intervention, starting with the two intervention
groups. After twelve months the two waiting list control
groups will sequentially start with PPA CMR.
Intervention
The intervention program “Personalized Prevention Ap-
proach for Cardiometabolic risk” (PPA CMR) is theicipants
n
ly performed screening for patients at risk for
metabolic disease
ing antihypertensive or lipid-lowering treatment
f the following ICPC-I-codes: K74: Angina pectoris, K75: Acute myocardial
ion, K76: Other chronic ischaemic heart disease, K77: Heart failure, K86:
plicated hypertension, K87: Hypertension with secondary organ damage,
ansient cerebral ischemia, K90: Stroke/cerebrovascular accident, K91:
sclerosis, K92: Peripheral vascular diseases, T90: Diabetes mellitus, T93:
etabolism disorder
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professional guideline ‘Preventive Consultation’ (PC) of
the Dutch College of General Practice [13] and a tailored
lifestyle intervention. PC is a Dutch prevention program
for CMD and has been developed for integration in pri-
mary care (in Dutch: ‘PreventieConsult Cardiometabool
risico’). In a pilot study in 2009 the PC has been tested
with regard to its feasibility and was positively evalu-
ated [8,15,17,24].
The intervention program of the INTEGRATE study
consists of several steps:
1. Invitation of patients to assess their CMD risk.
2. First step of screening: the online risk estimation
and lifestyle assessment.
3. Second step of screening: completing the CMD risk
profile with additional measurements.
4. Treatment of patients with an increased risk for CMD
with tailored lifestyle advise and/or medication.
Invitation of patients
All eligible patients receive an invitation from their GP
to participate in PPA CMR by completing an online risk
estimation and optionally an online lifestyle assessment.
To enhance participation rates, the accompanying infor-
mation letter will summarize the details of the study in
different languages. In case of non-response, a reminder
letter is sent after two weeks. Enclosed with the re-
minder letter is a paper version of the risk estimation.
The risk estimation and lifestyle assessment
The risk estimation is based on the widely accepted FIN-
DRISK score and is specified for predicting CMD in the
Dutch population [25,26]. This seven item-questionnaire
can be completed by self-report and assesses cardiometa-
bolic risk factors including age, gender, body mass index,
waist circumference, current family history of cardiovascu-
lar disease and/or diabetes [13,26]. The lifestyle assessment
consists of questions involving smoking, physical activity,
dietary patterns and willingness to change lifestyle [9,12].
The threshold in the risk estimation that will be used
is an absolute risk for developing CMD in the next seven
years of ≥ 23% for men and ≥ 19% for women [26]. Pa-
tients with scores below the threshold are at low risk
and receive online tailored lifestyle advice based on the
reported risk factors and the information provided in
the lifestyle assessment. All patients with scores above
the threshold are advised to complete their final risk
profile with additional measurements, by making an ap-
pointment at their general practice.
Completing the CMD risk profile
At the general practice, the risk profile is completed by
additional measurements: serum cholesterol level, fastingglucose level and blood pressure. During a second visit
the final risk profile is calculated based on the SCORE risk
estimation [27].
Treatment of patients with an increased risk for CMD
Patients will receive treatment according to their risk
profile, based on recommendations on lifestyle advice
and drug treatment from guidelines issued by the Dutch
College of GPs (including guidelines on cardiovascular
risk management, obesity management and diabetes
mellitus). Participating practices offer lifestyle interven-
tions in their own conventional manner, with the facil-
ities available to them. Possible facilities for lifestyle
interventions include the aid of a lifestyle coach to sup-
port active lifestyle change, offering structured programs
for smoking cession services, weight management or ex-
ercise programs and collaboration with other local initia-
tives in health programs.
Control group
Patients allocated to the waiting list control group re-
ceive an invitation from their GP - at the same moment
the first intervention group is invited- to participate in a
health study by completing an online questionnaire in-
cluding the questions of the risk estimation and lifestyle
assessment. However, these patients neither receive a
risk score, nor a specific lifestyle advice. These patients
will start with a one year waiting period, to be used as
control comparison. After a year they are invited to par-
ticipate in PPA CMR, starting with completing the risk
estimation and lifestyle assessment online. Hence, the
waiting list control group is offered the identical route
as the intervention group. Patients in the waiting list
control group receive normal standardized care during
the waiting period, including lifestyle advice or diagnos-
tics and treatment for CMD when indicated.
Response-enhancing strategies
During this study we will develop and evaluate different
response-enhancing strategies in subgroups of the wait-
ing list group. The response enhancing strategies are ad-
justed according to the results of non-response analyses
performed early in the study (see next paragraph, end-
point 5). Possible strategies include reminders by tele-
phone, translated questionnaires for non-Dutch speaking
patients, information gatherings at the general practice
and verbal reminders by the GP.
Another strategy is using a toolbox to complete the
final risk profile at home. It offers the option to bypass
one or both of the GP consultations. The toolbox con-
tains a blood pressure device and a laboratory test form.
Patients are asked to measure their blood pressure, visit
the laboratory and to complete the results online. In
case of a high blood pressure and/or elevated serum
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sult their GP. Patients without elevated biomedical risk
factors receive an online tailored lifestyle advice and will
therefore bypass both GP consultations. Like the other
response-enhancing strategies, the toolbox option will
be implemented during the intervention period of the
waiting list control group.
Endpoints and measurements
The endpoints of the INTEGRATE study are shown in
Table 2. An overview of all measurements is shown in
Figure 2.
For our secondary endpoints we will use the informa-
tion provided for our primary endpoints.



















staThe number of newly detected patients with
pre-existing CMD will be established after the
second consultation and after one year follow-up,
based on ICPC-1-coded diagnoses (see Table 1) in
the EMRs.2. Change in individual risk factors for CMD between
baseline and one year follow-up
For patients with an increased risk for CMD, risk
and lifestyle profiles will be established at the start of
PPA CMR and after twelve months of follow-up.
Risk profiles consist of the completed risk profile
including the additional measurements done by the
GP or with the self-management toolbox. The
questions of the online risk estimation and lifestyle
assessment are repeated after six months as well
(see Figure 2).e 2 Primary and secondary endpoints
ry endpoints Secondary endpoints
number of newly detected
ients with a CMD in one year
ow-up
1. Difference in primary outcome
5 after implementation of
different response-enhancing
strategies
nge in individual risk factors
oking, physical inactivity,
sity, unhealthy diet, blood
ssure and cholesterol levels)
CMD between baseline and
year follow-up
2. Change in willingness to
change lifestyle between
baseline and one year follow-up
expected number of newly
ected patients with CMD
mortality after 5, 10,20 years
lifetime
3. Change in health status
between baseline and one
year follow up
ts-effectiveness of PPA CMR
n-participation and
pliance in different
ges of PPA CMRFor patients with a low risk for CMD we will
establish risk and lifestyle profiles at the start of PPA
CMR and after twelve months of follow-up. These
risk profiles do not contain the additional
measurements.3. Expected newly detected patients with CMD and
mortality after 5, 10, 20 years and lifetime
We will use the RIVM-Chronic Disease Model
(RIVM-CDM) [28,29] to extrapolate the number of
possible prevented CMD due to PPA CMR with a
time horizon of 5, 10 and 20 years. The calculations
are based on changes in risk profile during one year
of treatment.4. Costs-effectiveness of PPA CMR
For patients with an increased risk for CMD, we will
establish health status, work status and absence
from work at the start of PPA CMR and after six
and twelve months of follow-up. Health status is
measured by the validated Dutch version of the
SF-36 [30] and the EQ-5D [31,32]. Work status and
absence from work is measured by using parts of the
Productivity Cost Questionnaire (iPCQ) [33].
Healthcare and non-healthcare costs are measured
after six and twelve months of follow-up. Healthcare
costs include the costs of implementing PPA CMR
and any lifestyle intervention or treatment that
emanates from the use of PPA CMR. Other
healthcare costs are the costs of health care
utilization during the one year follow-up. These
costs are based on standard prices for health care
use [34]. Non-healthcare costs include expenses
made by participants during the study, e.g. own
expenses for lifestyle interventions. Data on health
care use, needed for the economic evaluation, will be
extracted from EMR’s of GPs.
For patients with a low risk of CMD we will
establish health status, work status and absence
from work at the start of PPA CMR and after twelve
months of follow-up.
After completion of PPA CMR, the willingness to
pay for (parts of ) this program is evaluated in all
participants.5. Non-participation and compliance in different stages
of PPA CMR
Participation rates in the different phases of PPA
CMR are measured by establishing the number of
participants and the number of eligible patients in
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risk profile and during the treatment phase). Data
about the numbers of participants in each phase can
be derived from the website for online respondents.
The number of practice visits and compliance with
treatment is established at six and twelve month
with data from EMRs and self-reported compliance.
We will collect information on determinants of
response and non-response through the use of three
different sources. First, we will send questionnaires
to a random sample of patients who did not respond
to the invitation of their GP for participating in PPA
CMR (non-response group 1). This non-response
questionnaire contains items on health risk behavior,
assumptions about CMD and screening, reasons for
not participating and attitudes towards response-
enhancing strategies (see Table 3). In addition, we
will send a comparable online non-response
questionnaire to patients who scored above the
threshold on the online risk estimation, but did not
consult their GP (non-response group 2). Second,
we will extract anonymized data from EMRs,
including information on health care utilization of
both participants and non-participants. Finally, all
data will be linked with data from Statistics
Netherlands to obtain information about
socio-economic status (SES) and ethnic background.Information on determinants of non-participation and
successful completion of PPA CMR is used to study the
differences in characteristics of responders and non-
responders. We will also study differences in characteris-
tics of participating practices (e.g. urban/rural locations,
solo/group practices, organization of lifestyle interven-
tions) to find practice-related factors that are associated
with participation and compliance rates. The analyses of
determinants for participation shall be performed in the
first groups starting with the intervention. Depending one 3 Overview of measurements among
responders
response questionnaire T=0 T=12
stimation (paper) *
e risk estimation and lifestyle profile o o
de towards screening and treatment of CMD •
ns for non-participation •
de towards response-enhancing strategies •
y detected CMD (EMR) •
h care utilization (EMR) •
n-responders group 1 (no response to invitation PPA CMR, no online
timation).
n-responders group 2 (score above threshold on risk estimation, but not
consultation).
non-responders (group 1 + 2).the findings, response-enhancing strategies are devel-
oped and implemented in the waiting list control groups
that subsequently enter the study. Data collection for
subgroups receiving a response enhancing intervention
is done in the same way as described above.
Waiting list control group
From the waiting list control group we establish risk pro-
files, lifestyle assessment, health status, work status and
absence from work at baseline and again at the start of
PPA CMR one year later. At the start of PPA CMR newly
detected patients with CMD will be established, based
on ICPC-1-coded diagnoses in the EMRs. Patients who
develop a new CMD - documented through an ICPC-1-
coded diagnoses in the EMR - will not be eligible for par-
ticipation in PPA CMR, but will receive questionnaires for
follow-up. When the waiting list control group starts with
the intervention phase, the patients follow the identical
route as the intervention group (see Figure 2).
Analyses and statistical methods
We will analyze the data from this study according to
the intention-to-treat principle. Analyses will be per-
formed with all data available. Since the availability of
data will depend on the response rate, a fully complete
dataset cannot be expected. Multiple imputation tech-
niques are used for handling missing data.
Sample size calculation
Calculation of the sample size is based on the reduction
of smokers in the intervention group after one year
follow-up, one of the primary outcome measures. The
smoking prevalence in the Netherlands is 25% [35]. We
expect a reduction in smoking prevalence from 25% to
20% after one year treatment and a stable number of
smokers in the waiting list control group. In order to
achieve this reduction, 721 patients are needed in the
intervention group. This calculation is based on an alpha
of 0.05 (two-sided), a power of beta = 0.80 and a ratio
intervention group versus control group of 1:4). The 1:4
ratio represents a fair comparison between the interven-
tion and the large control group. Based on the pilot im-
plementation study of the PC, we expect approximately
21 patients per practice in the intervention group after
twelve months follow -up [14,15]. A low response rate
has been taken into account with this estimate. This
would result in the inclusion of 721/21 = 34 general
practices. However, in this study patients are clustered
within general practices and an oversampling of 15% is
needed to correct for this clustering in multi-level ana-
lyses. Therefore, we need approximately 40 general prac-
tices. The number of participants and practices will
result in sufficient power to establish statistically signifi-
cant differences between other subgroups.
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We will use multivariable multilevel regression analyses to
study the effects of PPA CMR on change in individual risk
factors and lifestyle and on the incidence of CMD after
one year follow-up. Therefore, we compare the interven-
tion group with the waiting list control group. In addition
we will evaluate the influence of different response enhan-
cing strategies on the effectiveness of PPA CMR. We will
use linear or logistic regression for continuous or dichot-
omous data, respectively. Multilevel analysis is needed to
correct for clustering of patients within practices.Cost-effectiveness of PPA CMR
We will perform an economic evaluation to relate net
incremental costs and effects of PPA CMR compared to
the waiting list control group. Estimated costs are based
on the healthcare and non-healthcare costs. After one
year of follow-up, cost-effectiveness of PPA CMR will be
established. To evaluate cost-effectiveness in the long
term, modeling is required. We will use the RIVM-
Chronic Disease Model (RIVM-CDM) to perform this
long-term economic evaluation. The RIVM-CDM is a
Markov-type, dynamic population-based model [28,29]
and is able to relate changes in prevalence of risk factors to
changes in future incidence of CMD. The model also con-
tains data on costs of cardiovascular events and associated
losses in quality of life. This model has extensively been
used for the evaluation of cost-effectiveness of prevention
programs targeted at lifestyle improvement [34,36-38].
The cost-effectiveness will be calculated per level of
change in individual risk factors. Incremental cost-
effectiveness ratios (ICER) are derived from calculating
the net costs of PPA CMR compared to the waiting list
control group, divided by its effect. In addition, we will
calculate the incremental cost-utility ratios (ICUR).
Therefore, the incremental costs of PPA CMR compared
to the waiting list control group will be divided by the
effects in quality adjusted life years (QALY’s) gained.
Utility values as incorporated in the RIVM-CDM will be
used for future cardiovascular events. Probabilistic sensi-
tivity analysis are performed for all calculations.Determinants of participation and compliance
The number of participants during the different phases
of PPA CMR will be presented with frequency tables.
Differences between participants and non-participants
regarding age, gender, SES, ethnic background, and car-
diometabolic risk are determined using univariable ana-
lysis (t-test, chi-square test). We will use descriptive
statistics and multivariable regression analyses to deter-
mine the profile of participants and non-participants in
PPA CMR.Privacy and informed consent
To ensure privacy of the patients, the participating prac-
tices will send the invitation letters to the patients. Add-
itional information in the invitation letter will inform the
participants about the study purposes. At the start of the
online risk estimation and lifestyle assessment, all patients
are asked to complete a digital informed consent form.
We will obtain data on health care utilization of all pa-
tients through data extraction from the EMR of the GPs.
Based on the Dutch law for data protection, obtaining
informed consent for this part of the data collection is
not necessary. All obtained data will be processed an-
onymous, not traceable to individual patients. The study
was considered by the UMC Utrecht Institutional
Review Board and exempted from full assessment under
the Medical Research involving human subjects Act.
Discussion
This manuscript describes the design of the INTEGRATE
study, a study aiming to establish the effectiveness and
cost-effectiveness of a Personal Prevention Approach for
cardiometabolic risk (PPA CMR) in primary care. An add-
itional aim is to provide more insight into the profile of
participants and non-participants and the effectiveness of
the various components of the program. Our final goal is
to contribute to the reduction of cardiometabolic morbid-
ity and mortality in an aging population.
Choices in study design
In the design of this study we made a number of choices
that need to be addressed:
1. Design
We have chosen a stepped-wedge randomized
controlled trial design. Patients will either be
allocated to the intervention group or the waiting
list control group that starts the intervention after
one year. The waiting list control group is necessary
to measure ‘natural’ changes in lifestyle among
eligible persons and to estimate the number of newly
detected CMD without exposure to PPA CMR.
At the end of the study PPA CMR is completely
implemented in all participating practices and all
eligible patients have received the intervention.
Implementation of PPA CMR is done in time
periods to distribute the workload for the GPs and
their staff.2. Randomization
Participants are not informed about the existence of
a waiting list control group and none of the
participants will know to which group they are
assigned. Nevertheless, the nature of this
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impossible. To minimize bias and maximize the
validity of the results, both groups will receive the
same standardized care, according to the evidence
based practice guidelines issued by the Dutch
College of GPs. For practical reasons, selection and
randomization of all eligible patients will be done at
baseline. Randomization is performed at individual
level and is done to equally distribute correlating
factors of patients registered within the same
practice. Because randomization takes place before
consenting to participate, selective response can be
induced (see ‘possible methodological threats’).
Randomization within practices can cause
‘contamination’, lifestyle changes of patients may
affect the lifestyle of their spouse and others in their
environment. When spouses are assigned to
different groups this can influence the results,
causing an underestimation of the effectiveness of
PPA CMR.3. Integration in routine primary care
Since PPA CMR is based on a Dutch GP guideline
and can be considered ‘standard care’, we have
chosen to implement PPA CMR into routine
primary care. This way we can evaluate the effects
of an existing screening program for patients at risk
for CMD combined with tailored treatment for risk
factors in the most natural way.4. Practice characteristics
Lifestyle interventions may differ between general
practices. For example, some practices have a
lifestyle coach or collaborate with local providers of
lifestyle interventions whereas in other practices GPs
only give lifestyle advice. Changes in lifestyle are
hard to accomplish, especially maintaining a healthy
lifestyle asks a lot of perseverance from patients.
Intensive support by a lifestyle coach or providing
local lifestyle interventions may provide the
necessary continuity to achieve a more sustainable
reduction in cardiometabolic risk. We will carefully
document practice characteristics to evaluate which
factors influence compliance with and enhance
effectiveness of the program.5. Modeling
One year of follow up will not be sufficient to fully
assess all the costs and benefits of PPA CMR.
Improvements in risk profile will only translate in a
reduction in cardiometabolic events in the longerterm. Modeling is therefore necessary to extrapolate
study findings to the longer term. The RIVM-CDM,
developed at the National Institute for Public Health
and the Environment, has been widely accepted for
evaluation of cost-effectiveness, also in other
prevention programs [34,36-38]. A disadvantage of
modeling is the potentially large effect of small
uncertainties of input data on the output of the
model. For instance, if the effect of PPA CMR on
patients’ risk profiles would decrease after one year,
this could result in an overestimation of the
long-term effects of the program. Probabilistic
sensitivity analysis will be performed to assess the
level of uncertainty of model outputs.Non-response analyses
The results of the non-response analyses of the INTE-
GRATE study will provide more information about the
characteristics and motives of non-participants in PPA
CMR. This knowledge is relevant and essential for the de-
velopment and evaluation of participation enhancing strat-
egies. The INTEGRATE study has a unique design where
the results of the non-response analyses, performed at an
early time point during the study, can be used as input for
developing interventions to increase the participation rate
later in the study. Effective participation enhancing strat-
egies are useful when optimizing implementation of future
prevention programs in primary care.
In comparable studies, including the pilot implementa-
tion of PC [14,15] the response rates were low, ranging
from 3% to 75% [14,15,18]. Since this has been taken into
account in the sample size calculation, sufficient power is
expected even with low response rates. To enhance par-
ticipation rates we plan to use several strategies, based on
advise and results of previous studies [14] and on non-
response analyses during the study. The accompanying in-
formation letter will emphasize safety in handling privacy
sensitive data, especially digital data. Furthermore, the in-
formation letter will contain a short recap of the purpose
of the letter and the advice to ask a family member for
help with translation if considered necessary. The letter
will present the recap in different languages. Reminder let-
ters with a paper version of the risk estimation will be sent
to all non-responders after two weeks. Furthermore, we
evaluate a subgroup that is offered the possibility to by-
pass one of the GP consultations by ordering a toolbox.
The toolbox is a tool that stimulates self-management; pa-
tients are able to take more responsibility for their own
health. Furthermore, obtaining the additional measure-
ments through a toolbox is easier to incorporate into ones
busy life and this might enhance participation rates. A
higher participation rate increases the cost-effectiveness of
the entire program.
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Several measures minimize possible bias in this study.
To prevent selection bias, we aim at a representative
sample for all GP practices in the Netherlands. Partici-
pating practices will be balanced in urban and rural loca-
tions and will have variable sizes, containing both solo
and group practices. Selective participation can be an
issue, since prevention programs sometimes tend to at-
tract the patients referred to as the ‘worried-well’
[14,18,39]. However, the pilot implementation of the
prevention program PC showed no presence of this ef-
fect [14,15]. The non-response analysis performed dur-
ing study is sensitive to selection bias in case of low
response rates and selective responders.
During this study participants are asked to report their
own expenses and health care utilization, including con-
sultations. Data collection by self-report can induce re-
call bias, but in combination with EMR data, we assume
the outcome measures to be more reliable.
Implementation challenges
Due to health care policy there is a possibility that changes
in the health care environment will occur over time. For
example, changes in established compensations for par-
ticipation in prevention programs by health care insurers
can influence the compliance and participation rates.
However, these changes will occur in both the interven-
tion groups and the waiting list control groups equally, so
we expect this will not influence our study results.
Conclusion
Prevention programs for CMD are an actual topic in
health care. Under pressure of politics and society, im-
plementation of these programs has already been initi-
ated. Nevertheless, primary prevention of CMD by early
risk factor modification has not yet been proven effective
and cost-effective at population level. Before implemen-
tation on a large scale can be carried out, scientific sup-
port must be presented. If the INTEGRATE study shows
PPA CMR to be effective and cost-effective, this will pro-
vide the evidence base that is needed for setting up pre-
vention programs for CMD at national level. With
determination of the profile of non-responders in pre-
vention programs in primary care, the results of the IN-
TEGRATE study will also assist in the development and
implementation of similar prevention programs.
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